R&D of NobelpharmaResearch & Development

Since the start of the business, Nobelpharma has been focusing on the research and development of medicines for unmet medical needs that other pharmaceutical companies do not engage in.
Our research and development subjects are selected with priority on those strongly requested by patient groups and academic societies, which are mainly orphan drugs (drugs for rare diseases) , off-labeled medicines, or pediatric medicines.
We are determined to further enhance our research and development system by stepping into medicines under new concepts and with a view to our globalization.

Why is Nobelpharma at the top level in Japan for the numbers of both orphan drug designations and new drug approvals?

Despite being a small company in business for just over 10 years with less than 250 employees, Nobelpharma has accomplished to be in top class in Japan on par with major pharmaceutical companies in each number of orphan drug designations (November 2003 - June 2014: in-house data) and new drug approvals (2008 - 2014: in-house data).

How is this possible?

The reason is our capability of searching and developing medicines and medical devices in the needs oriented approach.

1. Patient Needs First

Many of the pharmaceutical companies and ventures start their development of new medicines based on the research results of their own or universities, “seeds first” in other words.

On the other hand, “the patient needs comes first” for Nobelpharma. Placing top priority on serving such needs, we take the shortest path for development to “make the drugs available quickly.”

What we should also note is the fact that the active support from patients, specialists, and medical institutes undoubtedly provides us the significant driving force.

2. Specializing in Later-phase Development

Although we are a pharmaceutical company, we do not have any laboratories. Our so-called researchers without white coats in “Strategic Planning Division” evaluate the information collected from all around the world and determine the medicines that should be developed for patients in Japan.

This significantly reduces the time required for early-phase development allowing us to focus on later-phase development, which contributes to our fast development speed and the frequent approvals.

3. Meticulous “Schedule Management”

Our staff members set a deadline first before undertaking each task and those in research and development are no exceptions.

Each staff member always sets exact “dates” according to schedules for clinical trials, application filings, and expected approvals (Go to Pipeline), self-declaring the completion by specific “day, month, and year” no matter how long away and conducting oneself toward such a goal.

This does not mean we are forced to keep the schedule even if it becomes unreasonable. As we constantly confirm whether it is carried out on schedule relatively quickly, we set a new “date” whenever the schedule seems unrealistic and make steady progress in development taking a proactive approach.

4. Maintenance of Pleasant Working Environment for Selected Few

It is also a characteristic of Nobelpharma to have many experienced staff members, and the average age is rather high in the 50’s.

With experience in approval processes gained at major pharmaceutical companies, they know how to accomplish goals with the shortest route by utilizing their pertinent and extensive contacts acquired through many years of experience.

The capability of the research and development at Nobelpharma continues to enhance as such staff members fully display their skills and work every day on site with enthusiasm.

Page top